Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

Pharmacological treatment for psychotic depression

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: December 2021

In this Cochrane systematic review, researchers compared the clinical efficacy of pharmacological treatments for patients with acute psychotic depression to a placebo. They studied these treatments: 

  • Antidepressant monotherapy 
  • Antipsychotic monotherapy 
  • Mifepristone monotherapy 
  • Combination of an antidepressant plus an antipsychotic

Researchers also assessed whether differences in response to treatment in the current episode are related to non‐response to prior treatment.

Researchers found some evidence that combination therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or a placebo. They found limited evidence to assess treatment with an antidepressant alone or with an antipsychotic alone. Evidence to assess the efficacy of mifepristone is lacking.

Further, researchers pointed out that psychotic depression is heavily under‐studied, limiting confidence in these conclusions.

Read more about this resource

Objectives related to this resource (3)

Suggested Citation

1.

Kruizinga J, Liemburg E, Burger H, et al. (2021). Pharmacological treatment for psychotic depression. Retrieved from https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004044.pub5/full.